{
 "PrintNo":"S2682","Session":2023,"Chamber":"SENATE","BillType":"Senate","Published":"2023-01-24T10:30:40.798838Z",
 "Status":"IN_SENATE_COMM","Committee":"Insurance",
 "Milestones":[{"Type":"IN_SENATE_COMM","Date":"2024-01-03","Committee":"Insurance"}],
 "Actions":[
  {"Text":"REFERRED TO INSURANCE","Date":"2023-01-24","Chamber":"SENATE"},
  {"Text":"REFERRED TO INSURANCE","Date":"2024-01-03","Chamber":"SENATE"}
 ],
 "Sponsors":[
  {"ID":372,"Name":"Neil D. Breslin","Short":"BRESLIN"},{"ID":438,"Name":"Brad Hoylman-Sigal","Short":"HOYLMAN-SIGAL"},
  {"ID":1232,"Name":"James Skoufis","Short":"SKOUFIS"}
 ],
 "Title":"Relates to the applicability of step therapy to certain medically necessary prescription drugs",
 "Summary":"Ensures that step therapy shall not apply to medically necessary prescription drugs in the dermatologic, hematology, ophthalmologic, rheumatic, gastrointestinal, neurology, and oncology therapeutic classes, including non-formulary drugs.",
 "LawSection":"Insurance Law","LawCode":"Amd ยง4902, Ins L; amd ยง4902, Pub Health L",
 "ActClause":"AN ACT to amend the insurance law and the public health law, in relation to protecting certain therapeutic classes from step therapy",
 "SameAsPrintNo":"A582-2023","PreviousVersions":["S8193-2021"]
}